# US 2022/0010299 A1 · Systems and Methods to Enhance RNA Stability and Translation and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0010299 A1
- Document ID: US20220010299A1
- Status: Published application
- Kind: A1
- Application number: 17/364,890
- Filed: 2021-07-01
- Published: 2022-01-13
- Earliest claimed: 2020-07-13
- Assignees: The Board of Trustees of the Leland Stanford Junior University
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Rhiju Das; Christian A. Choe; Hannah K. Wayment-Steele; Wipapat Kladwang
- Web page: https://patentgrep.com/patent/US20220010299A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- C07K 14/005: from viruses
- C12N 15/67: General methods for enhancing the expression
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Embodiments herein describe systems and methods to enhance RNA translation and stability and uses thereof. Many embodiments generate RNA molecules possessing increased structure and/or reduced free energy over an initial sequence. Such RNA molecules can be used as therapeutics and/or vaccines.

## Claims

### Claim 1

An RNA therapeutic comprising:
an RNA molecule comprising a 5′ untranslated region, a 3′ untranslated region, and a coding sequence;
wherein the 5′ untranslated region is located 5′ of the coding sequence and the 3′ untranslated region is located 3′ of the coding sequence, and
wherein the coding sequence encodes for one or more viral epitopes.

### Claim 2 (depends on 1)

The RNA therapeutic of claim 1, wherein the coding sequence is selected from the group consisting of: SEQ ID NO: 5 and SEQ ID NOs: 437-439.

### Claim 3 (depends on 1)

The RNA therapeutic of claim 1, further comprising one or more of the group consisting of: a lubricant, a binder, a flavorant, and a coating.

### Claim 4 (depends on 1)

The RNA therapeutic of claim 1, further comprising a capsule selected from the group consisting of: a virus, a viroid, a virion, a capsid, a bacterium, a lipid nanoparticle, a micelle, a DNA structure, and an RNA structure.

### Claim 5 (depends on 1)

The RNA therapeutic of claim 1, wherein at least one nucleotide in the RNA molecule is replaced with an analog selected from the group consisting of: pseudouridine, 1-methyl-pseudouridine, and 5-methyl-cytidine, 1-methoxy-pseudouridine, and pseudo-isocytidine.

### Claim 6

A method for increasing RNA stability comprising:
obtaining a target RNA sequence comprising a coding sequence;
altering at least one nucleotide within the RNA sequence, wherein the altered sequence improves a metric correlated with improved RNA function; and
synthesizing an RNA molecule representing the altered sequence.

### Claim 7 (depends on 6)

The method of claim 6, wherein the altering step is performed by:
sampling a nucleotide within the target coding sequence, wherein the sampled nucleotide comprises an unpaired nucleotide within the coding sequence; and
substituting the sampled nucleotide with a new nucleotide to create a substituted coding sequence.

### Claim 8 (depends on 6)

The method of claim 6, wherein the altered sequence possesses increased structure over the target coding sequence.

### Claim 9 (depends on 6)

The method of claim 6, wherein the metric is selected from the group consisting of: free energy (dG) of an RNA molecule conformation, dG of the ensemble (dG(ensemble)), codon adaptation index (CAI), and expected Matthews Correlation Coefficient (MCC).

### Claim 10 (depends on 6)

The method of claim 6, wherein the metric is selected from the group consisting of: maximum ladder distance (MLD), unpaired nucleotides, GC content, number of hairpins, number of 3-way junctions (3WJs), number of 4-way junctions, (4WJs), number of 5-way junctions (5WJs), ratios of hairpins to junctions, number of unpaired nucleotides, kissing loops, pseudoknots, tertiary contacts, multimeric designs, dimerization domains, and symmetrical structures.

### Claim 11 (depends on 6)

The method of claim 6, wherein the metric is selected from the group consisting of: mean base pair proximity, probability of unpaired nucleotides, sum of paired bases, increased structure, summed probability of being unpaired, and predicted degradation score.

### Claim 12 (depends on 6)

The method of claim 6, wherein the substituted coding sequence possesses a lower free energy than the target coding sequence.

### Claim 13 (depends on 6)

The method of claim 6, wherein the target RNA sequence comprises at least one of the group consisting of: a poly-A tail, a 5′ untranslated region, and a 3′ untranslated region.

### Claim 14 (depends on 6)

The method of claim 6, wherein the substituting step uses a greedy GC strategy, where if a C or G substitution is possible, the nucleotide is substituted for the nucleotide.

### Claim 15 (depends on 6)

The method of claim 6, wherein the altered sequence possesses a lower DegScore than the target RNA sequence, wherein
DegScore=a*[stem nts]+b*[internal loop nts]+c*[hairpin nts]+d*[bulge nts]+e*[multiloop nts]+f*[exterior loop nts],
where nts stands for nucleotides, and
a-f represent coefficients for relative reactivity of nucleotides within a particular structure.

### Claim 16 (depends on 6)

The method of claim 6, further comprising transfecting a cell with the synthesized RNA molecule.

### Claim 17 (depends on 6)

The method of claim 6, further comprising treating an individual with the synthesized RNA molecule.

### Claim 18 (depends on 17)

The method of claim 17, wherein the synthesized RNA molecule is formulated for medical use.

### Claim 19 (depends on 18)

The method of claim 18, wherein the synthesized RNA molecule is formulated by combining the synthesized RNA molecule with at least one of the group consisting of: a lubricant, a binder, a flavorant, and a coating.

### Claim 20 (depends on 18)

The method of claim 18, wherein the synthesized RNA molecule is encapsulated in at least one of the group consisting of: a virus, a viroid, a virion, a capsid, a bacterium, a lipid nanoparticle, a micelle, a DNA structure, and an RNA structure.

### Claim 21 (depends on 6)

The method of claim 6, wherein altering at least one nucleotide within the RNA sequence comprises replacing at least one nucleotide in the RNA sequence with an analog selected from the group consisting of: pseudouridine, 1-methyl-pseudouridine, and 5-methyl-cytidine, 1-methoxy-pseudouridine, and pseudo-isocytidine.

### Claim 22 (depends on 6)

The method of claim 6, wherein altering at least one nucleotide is iterated at least 100 times.

### Claim 23

An RNA molecule to transfect a cell comprising: a 5′ untranslated region, a 3′ untranslated region, and a coding sequence, wherein the 5′ untranslated region is located 5′ of the coding sequence and the 3′ untranslated region is located 3′ of the coding sequence.

### Claim 24 (depends on 23)

The RNA molecule of claim 23, wherein the coding sequence codes for one or more viral epitopes.

### Claim 25 (depends on 24)

The RNA molecule of claim 24, wherein the coding sequence is selected from the group consisting of: SEQ ID NO: 5 and SEQ ID NOs: 437-439.

### Claim 26 (depends on 23)

The RNA molecule of claim 23, wherein the coding sequence codes for green fluorescence protein.

### Claim 27 (depends on 26)

The RNA molecule of claim 26, wherein the coding sequence is selected from the group consisting of: SEQ ID NO: 8 and SEQ ID NOs: 12-236.

### Claim 28 (depends on 23)

The RNA molecule of claim 23, wherein the coding sequence codes for nanoluciferase.

### Claim 29 (depends on 28)

The RNA molecule of claim 28, wherein the coding sequence is selected from the group consisting of SEQ ID NOs: 237-436.

### Claim 30 (depends on 23)

The RNA molecule of claim 23, wherein at least one nucleotide in the RNA molecule is replaced with an analog selected from the group consisting of: pseudouridine, 1-methyl-pseudouridine, and 5-methyl-cytidine, 1-methoxy-pseudouridine, and pseudo-isocytidine.
